Isis Nabs $6M Bristol Payment

Xconomy San Diego — 

Isis Pharmaceuticals (NASDAQ: ISIS), the Carlsbad, CA-based biotech company, said today it has earned a $6 million payment from Bristol-Myers Squibb for getting clearance from regulators to begin clinical trials of a new cholesterol-lowering drug. Isis and Bristol are collaborating on BMS-PCSK9Rx, as a targeted antisense therapy which seeks to lower cholesterol by hitting the target PCSK9.